Viking Therapeutics, Inc.VKTX

Market cap

$3.9B

P/E ratio

	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Cash and cash equivalents	768,550	3	9	25	8	29	26	37	56	27
Short-term investments – available for sale	-	-	-	-	-	-	176	119	307	876
Prepaid clinical trial and preclinical study costs	-	-	-	0	7	7	8	8	3	3
Prepaid expenses and other current assets	1	824,269	388,969	0	0	0	1	3	3	1
Total current assets	15	14	22	302	284	256	211	167	367	907
Right-of-use assets	-	-	-	-	1	0	0	1	1	1
Deferred financing costs	-	-	-	-	-	-	-	0	0	0
Deposits	80,000	39,341	-	0	0	0	0	0	0	0
Total assets	15	15	22	302	284	257	211	169	368	908
Accounts payable	592,414	1	2	1	2	4	1	9	8	10
Other accrued liabilities	1	1	2	4	4	8	7	13	11	17
Lease liability, current	-	-	-	-	0	0	0	0	0	0
Total current liabilities	2	6	9	5	7	12	9	22	19	27
Operating Lease, Liability, Noncurrent	-	-	-	-	0	0	-	1	1	1
Total long-term liabilities	5	16,307	-	0	0	0	-	1	1	1
Total liabilities	7	6	9	5	7	12	9	23	20	28
Common Stock, Value, Issued	97	208	358	0	0	0	0	0	0	0
Treasury stock at cost, no shares at December 31, 2024 and 2,193,251 shares at December 31, 2023	-	-	-	-	-	-	-	7	7	-
Additional paid-in capital	54	68	94	401	406	413	426	445	734	1,369
Accumulated deficit	-45,545,445	-60,277,267	-80,854,932	-103	-129	-168	-223	-292	-378	-488
Accumulated other comprehensive loss	-7,370	-6,892	-19,769	-0	0	-0	-1	-1	-0	-1
Total stockholders’ equity	9	8	13	298	277	244	202	145	348	880
Total liabilities and stockholders’ equity	15	15	22	302	284	257	211	169	368	908